While Haemonetics Corp. has underperformed by -2.52%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HAE fell by -6.16%, with highs and lows ranging from $95.26 to $70.74, whereas the simple moving average fell by -14.74% in the last 200 days.
On October 13, 2022, Mizuho started tracking Haemonetics Corp. (NYSE: HAE) recommending Buy. A report published by Needham on January 27, 2022, Downgraded its rating to ‘Hold’ for HAE. Citigroup also Downgraded HAE shares as ‘Neutral’, setting a target price of $59 on the company’s shares in a report dated December 15, 2021. Raymond James Initiated an Outperform rating on August 17, 2021, and assigned a price target of $75. Citigroup initiated its ‘Buy’ rating for HAE, as published in its report on June 17, 2021. Morgan Stanley also rated the stock as ‘Equal-Weight’.
Analysis of Haemonetics Corp. (HAE)
Further, the quarter-over-quarter increase in sales is 10.14%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Haemonetics Corp.’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 14.72% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.76, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 394.41K can be a very valuable indicator of volatility for HAE stock. On a monthly basis, the volatility of the stock is set at 3.38%, whereas on a weekly basis, it is put at 2.83%, with a loss of -2.56% over the past seven days. Furthermore, long-term investors anticipate a median target price of $105.83, showing growth from the present price of $72.98, which can serve as yet another indication of whether HAE is worth investing in or should be passed over.
How Do You Analyze Haemonetics Corp. Shares?
The USA based company Haemonetics Corp. (HAE) is one of the biggest names in Medical Instruments & Supplies. When comparing Haemonetics Corp. shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 29.61, there is a growth in quarterly earnings of -5.58%.
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.06%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 100.38% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
HAE shares are owned by institutional investors to the tune of 100.38% at present.
